Health-Related Quality of Life in EORTC clinical trials - 30 years of progress from methodological developments to making a real impact on oncology practice

European Journal of Cancer, Supplement

Volumn 10, Issue 1, 2012, Pages 141-149

  Velikova, G ^a   Coens, C ^b   Efficace, F ^c   Greimel, E ^d   Groenvold, M ^e,f   Johnson, C ^g   Singer, S ^h,i   van de Poll Franse, L ^j,k   Young, T ^l   Bottomley, A ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b EORTC DATA CENTER   (Belgium)

^c Sardar Patel Postgraduate Institute of Dental and Medical Sciences   (India)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e BISPEBJERG HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^h UNIVERSITY OF WUPPERTAL   (Germany)

ⁱ UNIVERSITY OF LEIPZIG   (Germany)

^j Eindhoven Cancer Registry   (Netherlands)

^k TILBURG UNIVERSITY   (Netherlands)

^l MOUNT VERNON CANCER CENTRE   (United Kingdom)

more..

Author keywords

Clinical trials; Health related quality of life; Questionnaire

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); EORTC QLQ C30 QUESTIONNAIRE; PRIORITY JOURNAL; PROCESS DESIGN; QUALITY OF LIFE INDEX; QUESTIONNAIRE; SYSTEMATIC REVIEW;

EID: 84863393477     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/S1359-6349(12)70023-X     Document Type: Article

References (37)

1. Bottomley A, Flechtner H, Efficace F, et al. Health related quality of life outcomes in cancer clinical trials. Eur J Cancer 2005, 41(12):1697-1709.
2. Aaronson NK Quality of life: what is it?. How should it be measured? Oncology 1988, 2(5):69-76. 64.
3. Aaronson NK, Bullinger M, Ahmedzai S A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results Cancer Res 1988, 111:231-249.
4. Sprangers MA, Cull A, Bjordal K, Groenvold M, Aaronson NK The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res 1993, 2(4):287-295.
5. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376.
6. Osoba D, Rodrigues G, Myles J, Zee B, Pater J Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16(1):139-144.
7. King MT The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996, 5(6):555-567.
8. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011, 29(1):89-96.
9. Maringwa JT, Quinten C, King M, et al. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer 2011, 19(11):1753-1760.
10. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol 2003, 21(15):2982-2992.
11. Efficace F, Bottomley A, van Andel G Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 2003, 97(2):377-388.
12. Gotay CC, Kawamoto CT, Bottomley A, Efficace F The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008, 26(8):1355-1363.
13. Koller M, Aaronson NK, Blazeby J, et al. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer 2007, 43(12):1810-1820.
14. Bottomley A, Vachalec S, Bjordal K, Blazeby J, Flechtner H, Ruyskart P The development and utilisation of the European Organisation for Research and Treatment of Cancer Quality of Life Group item bank. Eur J Cancer 2002, 38(12):1611-1614.
15. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009, 27(1):78-84.
16. Taphoorn MJ, van den Bent MJ, Mauer ME, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 2007, 25(36):5723-5730.
17. Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005, 6(12):937-944.
18. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009, 27(18):2916-2923.
19. Bottomley A, Gaafar R, Manegold C, et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 2006, 24(9):1435-1442.
20. Bottomley A, Therasse P, Piccart M, et al. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol 2005, 6(5):287-294.
21. Bottomley A, Biganzoli L, Cufer T, et al. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 2004, 22(13):2576-2586.
22. van Herpen CM, Mauer ME, Mesia R, et al. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer 2010, 103(8):1173-1181.
23. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363(10):943-953.
24. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009, 10(9):865-871.
25. Efficace F, Bottomley A, Collins GS Quality of life in breast cancer patients: measurement issues in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res 2002, 2(1):57-65.
26. Efficace F, Bottomley A Toward a clearer understanding of the prognostic value of health-related quality-of-life parameters in breast cancer. J Clin Oncol 2005, 23(6):1335-1336. author reply: 1336.
27. Efficace F, Bottomley A, Vanvoorden V, Blazeby JM Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 2004, 40(2):187-197.
28. Efficace F, Bottomley A, Osoba D, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 2003, 21(18):3502-3511.
29. Efficace F, Bottomley A Do quality-of-life randomized clinical trials support clinicians in their decision-making?. J Clin Oncol 2002, 20(19):4126-4127. author reply: 4127.
30. Scott NW, Fayers PM, Bottomley A, et al. Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses. Qual Life Res 2006, 15(6):1103-1115. discussion 1117-20.
31. Scott NW, Fayers PM, Aaronson NK, et al. The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30. Qual Life Res 2007, 16(1):115-129.
32. Scott NW, Fayers PM, Aaronson NK, et al. The relationship between overall quality of life and its subdimensions was influenced by culture: analysis of an international database. J Clin Epidemiol 2008, 61(8):788-795.
33. Scott NW, Fayers PM, Aaronson NK, et al. A simulation study provided sample size guidance for differential item functioning (DIF) studies using short scales. J Clin Epidemiol 2009, 62(3):288-295.
34. Petersen MA, Groenvold M, Aaronson NK, et al. Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimension. Qual Life Res 2011, 20(4):479-490.
35. Petersen MA, Groenvold M, Aaronson NK, et al. Development of computerised adaptive testing (CAT) for the EORTC QLQ-C30 dimensions - general approach and initial results for physical functioning. Eur J Cancer 2010, 46(8):1352-1358.
36. Giesinger JM, Petersen MA, Groenvold M, et al. Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients. Health Qual Life Outcomes 2011, 9(1):19.
37. Erharter A, Giesinger J, Kemmler G, et al. Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage 2010, 39(2):219-229.